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Background: Maternal diabetes may be linked to childhood acute lymphoblastic leukaemia (ALL) in the offspring.
Methods: We assessed the association between maternal pregestational or gestational diabetes and offspring risk of childhood
ALL in a register-based study, including all singletons born in Denmark during 1996–2015 (n¼ 1 187 482).
Results: Adjusted hazard ratios of childhood ALL were 2.91 (95% confidence interval (CI): 1.30–6.51) for maternal pregestational
diabetes and 1.75 (95% CI: 1.02–2.98) for maternal gestational diabetes. Paternal diabetes did not alter offspring ALL risk, and we
found no association between offspring ALL and later maternal risk of diabetes.
Conclusions: Regardless that absolute ALL risk among offspring of women with diabetes remains low, our findings suggest that
characteristics of the diabetic intrauterine environment promote ALL development. This offers a setting for future research into the
biological mechanisms underlying childhood ALL.
Acute lymphoblastic leukaemia (ALL) is the commonest childhood
cancer, with an annual incidence of approximately 4 in 100 000
person-years among children below 15 years of age in developed
countries (Hjalgrim et al, 2003a; Stiller et al, 2006). Apart from
certain genetic syndromes, accounting for less than 5% of cases
(Stieglitz and Loh, 2013) and a well-established association with
high birth weight (Hjalgrim et al, 2003b; Caughey and Michels,
2009), risk factors for childhood ALL remain largely unknown. The
prenatal origin of most childhood ALL cases has been irrefutably
demonstrated by the presence of clone-specific mutations in
patient neonatal blood spots (Wiemels et al, 1999; Hjalgrim et al,
2002; Gruhn et al, 2008). While the intrauterine development of
preleukaemic cell clones remains unexplained, the association
between birth weight and childhood ALL risk suggests that it is
related to foetal growth. In addition, a recent study reported an
increased ALL risk in children born to women with diabetes
(Contreras et al, 2016), whose offspring are at increased risk of
macrosomia (Schmidt et al, 2001; Crowther et al, 2005; Temple
et al, 2006). However, it is unclear whether this association varies
by type of maternal diabetes and between ALL subtypes, which
may have distinct aetiologies.
We therefore evaluated the risk of ALL among offspring of
women with pregestational or gestational diabetes in a cohort
study, including all singletons born in Denmark during 1996–2015
identified using nationwide registers with detailed information on
maternal antidiabetic medication and ALL subtypes.
MATERIALS AND METHODS
Based on the unique personal identifiers of the children and their
parents, we linked information on birth characteristics obtained
from the Danish Medical Birth Register (Knudsen and Olsen,
1998) with information on maternal diabetes recorded in the
Danish National Patient Register (NPR) (Lynge et al, 2011). The
NPR contains records of all hospitalisations since 1977, including
outpatient contacts since 1995 with diagnoses classified according
to the International Classification of Diseases (ICD) 8th (1977–
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1993) and 10th revision (1994–). Children registered with Down
syndrome in the NPR (ICD10 code Q90) were excluded from the
cohort (0.08%) due to their increased risk of childhood leukaemia
with distinct biology and aetiology (Izraeli et al, 2014).
We defined maternal pregestational diabetes as NPR registra-
tions of ICD8 codes 249 or 250, or ICD10 codes E10–E11 or
E13–E14 before gestation. Gestational diabetes was defined as any
of the listed ICD codes for diabetes registered for the first time
during pregnancy including also ICD10 code O24. For women
registered with pregestational diabetes, we retrieved additional
information on first-time prescriptions for antidiabetic treatment
from the Danish Register of Medicinal Product Statistics
(established 1995) (Anatomic Therapeutic Chemical classification
system codes A10A for insulin and A10B for oral antidiabetic
medications).
ALL occurring before age 15 years was identified through
linkage with the Nordic Society of Paediatric Haematology and
Oncology leukaemia database (Schmiegelow et al, 2010).
The children were followed from birth until date of childhood
ALL diagnosis, loss to follow-up/emigration, death, age 15 years, or
31 December 2015, whichever occurred first. We used Cox
proportional hazards models with age as the underlying time scale
to estimate hazard ratios (HRs) for childhood ALL.
Based on the potential of association with both maternal
diabetes and childhood ALL, we adjusted for a number of
covariates identified in the Danish Medical Birth Register and
the Danish Civil Registration System (Pedersen, 2011). These
included the potential confounders maternal age at delivery
(continuous), ethnicity (Danish or other), birth order (1, 2 or
X3), maternal smoking during pregnancy (yes or no) and birth
cohort (5-year intervals), and the potential mediators birth weight
(100-g intervals), gestational age (1-week intervals) and mode of
delivery (caesarean section or vaginal) (Hjalgrim et al, 2004; Chang
et al, 2006; Thomopoulos et al, 2015; Contreras et al, 2017).
Further, we tested the heterogeneity of the association between
maternal diabetes and offspring risk of ALL by birth weight using
the median as cut-off (o3540 g vs X3540 g).
Childhood ALL was grouped as: (1) all types combined; (2)
B-cell precursor ALL; (3) and a group comprising the frequent,
prenatally initiated karyotypes (ETV6/RUNX1-positive and high-
hyperdiploidy ALL).
In subsequent analyses we tested whether paternal diabetes was
associated with childhood ALL. Also, we assessed the risk of
developing diabetes in women with and without offspring with
ALL. In this analysis, we included women with X1 live births
between 1996 and 2015, followed from their first birth after 1995
until diabetes diagnosis (outcome), death, emigration, or 31
December 2015, excluding women with diabetes diagnosed before
start of follow-up. History of offspring ALL was included as a time-
varying variable (exposed from date of offspring ALL diagnosis)
with adjustment for maternal age, parity and year of delivery.
All analyses were conducted using SAS statistical software (9.4,
SAS Institute, Inc., Cary, NC, USA) with 95% confidence intervals
(CIs) based on Likelihood-ratio tests.
Table 1. Person-years of follow-up and number of cases of childhood acute lymphoblastic leukaemia (ALL), according to baseline
characteristics and parental diabetes among singletons born in Denmark during 1996–2015









Total 11 196 998 (100) 492 (100) 431 (100) 266 (100) 1 187 482 (100)
Sex
Boys 5 745 498 (51.3) 262 (53.3) 222 (51.5) 145 (54.5) 609 514 (51.3)
Girls 5 451 500 (48.7) 230 (46.7) 209 (48.5) 121 (45.5) 577 968 (48.7)
Ethnicity
Danish 9 334 246 (83.4) 423 (86.0) 370 (85.8) 233 (87.6) 966 532 (81.4)
Other 1 862 752 (16.6) 69 (14.0) 61 (14.2) 33 (12.4) 220 950 (18.6)
Birth order
1 4 863 355 (43.4) 223 (45.3) 196 (45.5) 116 (43.6) 521 866 (44.0)
2 4 184 761 (37.4) 183 (37.2) 162 (37.6) 104 (39.1) 442 240 (37.2)
X3 2 148 882 (19.2) 86 (17.5) 73 (16.9) 46 (17.3) 223 376 (18.8)
Maternal smoking
No 9 292 764 (83.0) 424 (86.2) 374 (86.8) 229 (86.1) 1 003 943 (84.5)
Yes 1 904 234 (17.0) 68 (13.8) 57 (13.2) 37 (13.9) 183 539 (15.5)
Birth weight (g)a 3601 3588 3578 3524
Gestational age (weeks)a 39.5 39.4 39.3 39.4
Mode of delivery
Vaginal 9 359 216 (83.6) 400 (81.3) 350 (81.2) 208 (78.2) 974 473 (82.1)
Caesarean section 1 837 782 (16.4) 92 (18.7) 81 (18.8) 58 (21.8) 213 009 (17.9)
Maternal diabetes
No 10 976 192 (98.0) 472 (95.9) 415 (96.3) 253 (95.1) 1 157 767 (97.5)
Pregestational 46 598 (0.4) 6 (1.3) 5 (1.2) 4 (1.5) 5409 (0.5)
Gestational 174 208 (1.6) 14 (2.8) 11 (2.5) 9 (3.4) 24 306 (2.0)
First-time pregestational diabetes treatment
Insulin 35 000 (75.1) 5 (83.3) 5 (100) 4 (100) 3857 (71.3)
Age at pregestational diabetes diagnosis
o30 40 081 (86.0) 6 (100) 5 (100) 4 (100) 4554 (84.2)
X30 6517 (14.0) 0 (0) 0 (0) 0 (0) 855 (15.8)
Paternal diabetesb
No 10 963 593 (98.7) 482 (98.6) 423 (98.8) 261 (99.2) 1 165 777 (98.2)
Yes 148 517 (1.3) 7 (1.4) 5 (1.2) 2 (0.8) 21 435 (1.8)
Abbreviations: ALL¼ acute lymphoblastic leukaemia; BCP¼B-cell precursor ALL; ETV6/RUNX1¼ETV6/RUNX1-positive ALL; HeH¼high-hyperdiploidy ALL.
aMean.
bPaternal diabetes diagnosed at any time before end of follow-up, including 1 187 212 singletons whose fathers were known from the Civil Registration System.
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RESULTS
Among 1 187 482 studied singletons, 492 developed ALL before age
15 years (Table 1), corresponding to an annual incidence rate of 4.40
(95% CI: 4.02–4.80) per 100 000 person-years. In total, 5409 children
were born to women with pregestational diabetes (mean birth weight:
3519 g) of whom six developed ALL (mean birth weight: 3894 g;
mean age at diagnosis: 4.2 years, age range 2–8 years). All mothers to
these six children with ALL were diagnosed with diabetes before age
30 years and five mothers had received insulin as first-time
antidiabetic treatment. Further, we identified 24 306 children born
to women with gestational diabetes (mean birth weight: 3537 g) of
whom 14 developed ALL (mean birth weight: 3707 g; mean age at
diagnosis: 3.4 years, age range 1–7 years).
After adjusting for potential confounders, childhood ALL risk
among children born to women with pregestational or gestational
diabetes was 2.91-fold (95% CI: 1.30–6.51) and 1.75-fold (95% CI:
1.02–2.98) increased, respectively, compared with children born to
nondiabetic women (Table 2). In analysis of pregestational diabetes,
HR were statistically significantly increased for B-cell precursor ALL
and for the prenatally initiated karyotypes (ETV6-RUNX1 or high-
hyperdiploidy ALL), while HRs associated with gestational diabetes
were only statistically significantly increased among the prenatally
initiated karyotypes. The risk estimates remained unchanged in
models including only potential confounders (Table 2) and both
potential confounders and mediators, respectively (data not shown).
HRs for ALL associated with gestational diabetes did not differ
in strata of birth weight (birth weighto3540 g: HR¼ 1.68, 95% CI:
0.75–3.81 vs birth weight X3540 g: HR¼ 1.78, 95% CI: 0.88–3.61;
p for interaction¼ 0.92). Neither did we find statistically significant
differences between the HRs for ALL associated with pregestational
diabetes stratified by birth weight (birth weight o3540 g:
HR¼ 1.10, 95% CI: 0.16–7.87 vs birth weight X3540 g:
HR¼ 4.30, 95% CI: 1.77–10.43; p for interaction¼ 0.16).
Paternal diabetes was not statistically significantly associated
with childhood ALL risk (HR¼ 1.20, 95% CI: 0.57–2.53) (Table 2).
Finally, we found no association between offspring ALL and later
risk of diabetes in the mother (HR¼ 0.92, 95% CI: 0.46–1.85, based
on eight mothers diagnosed with diabetes after offspring ALL).
DISCUSSION
In this nationwide register-based cohort study, we found that the
risk of childhood ALL in children born to women with
pregestational or gestational diabetes was 2.9- and 1.7-fold
increased, respectively.
The observed association with pregestational diabetes in our study
is likely attributable to type 1 diabetes because the vast majority of
these women had received insulin as first-time antidiabetic treatment
and were diagnosed before age 30 years. However, the fact that
gestational diabetes was also associated with offspring ALL risk
suggests that the association with maternal diabetes is not exclusively
related to the autoimmunity of type 1 diabetes.
Because of its level of detail regarding both maternal diabetes and
offspring ALL, our investigation expands the existing literature on the
association between the two conditions considerably. Recently, a
statistically significantly 1.4-fold increased ALL risk in offspring of
women with pregestational diabetes and a statistically non-
significantly 1.3-fold increased ALL risk in offspring of women with
gestational diabetes were observed in a California birth record study
(Contreras et al, 2016). However, unlike in our investigation,
information was available on neither type of pregestational diabetes
nor on ALL subtypes in the California study. Limitations of similar
nature concerning exposure and outcome combined with small study
populations have hampered the interpretation of other previous
investigations reporting statistically non-significantly increased risks
of ALL (McLaughlin et al, 2006; Milne et al, 2007) or of leukaemia
(Petridou et al, 1997; Podvin et al, 2006) or statistically significantly
increased risks of cancer overall (Westbom et al, 2002; Wu et al,
2012) in offspring of women with diabetes.
Not mirrored by similarly strong associations with paternal
diabetes or later maternal diabetes, the increased ALL risk in
children born to women with diabetes is unlikely to reflect shared
genetic risk factors; rather it may reflect that circumstances
characteristic of diabetic pregnancies such as intrauterine hyper-
glycaemia promote offspring ALL development. In support hereof,
we observed that children born to women with pregestational
diabetes who developed ALL weighed on average 400 g more than
those who did not, suggesting that maternal hyperglycaemia was
more pronounced in the former. Birth weight is positively
associated with the level of insulin-like growth factor I, which
could increase childhood ALL risk by causing proliferation of
progenitor or preleukaemic cells (Ross et al, 1996). Moreover,
maternal hyperglycaemia has been associated with a number of
epigenetic modifications in the offspring (Ma et al, 2015), which
potentially mediate the link between maternal diabetes and
offspring’s development of ALL.
Although we observed markedly increased relative risks, the
cumulative incidence of childhood ALL in offspring of women with
diabetes remains low, that is, 0.15 and 0.08% among children
Table 2. Association between maternal diabetes, paternal diabetes and risk of childhood acute lymphoblastic leukaemia (ALL)















No (ref.) 1.00 1.00 1.00 1.00 1.00 1.00
Pregestational 2.92 (1.30–6.53) 2.91 (1.30–6.51) 2.76 (1.14–6.66) 2.75 (1.14–6.65) 3.61 (1.35–9.68) 3.58 (1.33–9.62)
Gestational 1.73 (1.02–2.95) 1.75 (1.02–2.98) 1.54 (0.85–2.80) 1.56 (0.85–2.84) 2.04 (1.05–3.97) 2.06 (1.05–4.03)
Paternal diabetesc
No (ref.) 1.00 1.00 1.00 1.00 1.00 1.00
Yes 1.23 (0.58–2.59) 1.20 (0.57–2.53) 1.01 (0.42–2.45) 0.99 (0.41–2.39) 0.68 (0.17–2.71) 0.66 (0.16–2.65)
Abbreviations: ALL¼ acute lymphoblastic leukaemia; BCP¼B-cell precursor ALL; CI¼ confidence interval; ETV6/RUNX1¼ETV6/RUNX1-positive ALL; HeH¼ high-hyperdiploidy ALL; HR¼
hazard ratio. Crude HRs were implicitly adjusted for age (underlying time scale).
aHRs were adjusted for maternal age at delivery (linearly), ethnicity (Danish or other), birth order (1, 2, or X3), maternal smoking (yes or no), and birth cohort (5-year intervals).
bThe cumulative incidence of ALL before age 15 years was 0.15% (95% CI: 0.06–0.33) among children born to women with pregestational diabetes, 0.08% (95% CI: 0.05–0.14) among children
born to women with gestational diabetes, and 0.05% (95% CI: 0.05–0.06) among children born to nondiabetic women (calculations based on Kaplan–Meier estimators).
cPaternal diabetes diagnosed at any time before end of follow-up, including 1 187 212 singletons whose fathers were known from the Civil Registration System. HRs were adjusted for paternal
age at delivery (linearly), ethnicity (Danish or other), birth order (1, 2, or X3) (same mother), and birth cohort (5-year intervals).
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below 15 years of age born to women with pregestational and
gestational diabetes, respectively.
The strengths of this study include its nationwide coverage,
longitudinal and independent ascertainment of maternal diabetes
and offspring ALL development as well as information on
important covariates including birth weight. Contrary to previous
investigations, our study included information on pregestational
diabetes treatment and detailed information on ALL subtypes.
Conversely, the low number of children with ALL born to women
with pregestational or gestational diabetes had implications for the
precision of risk estimates, reflected by the wide CIs. Finally, the
apparent absence of association with paternal diabetes or later
maternal diabetes was based on a small number of exposed events.
In conclusion, we found that maternal pregestational and
gestational diabetes are risk factors for childhood ALL in the
offspring. Further studies are needed to identify the biological
mechanisms underlying this association.
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